odalasvir
Small moleculeexperimental
Odalasvir is an investigational new drug in development for the treatment of hepatitis C. It is an NS5A inhibitor. The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure. It is under development by Achillion Pharmaceuticals. — Wikipedia
Clinical trial activity
15 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2012 (NCT01700179)
Timeline
Indications
Mechanism of action
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
- Nonstructural protein 5AINHIBITOR
Nonstructural protein 5A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)N[C@H](C(=O)N1[C@H](c2nc3cc(-c4cc5ccc4CCc4ccc(c(-c6ccc7[nH]c([C@@H]8C[C@@H]9CCCC[C@@H]9N8C(=O)[C@@H](NC(=O)OC)C(C)C)nc7c6)c4)CC5)ccc3[nH]2)C[C@@H]2CCCC[C@@H]21)C(C)C- Mol. weight
- 1001.29 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOdalasvir ↗
- ChEMBLCHEMBL3544977 ↗
Also known as
- ach-0143102
- ach-0143102
- ach-0143102
- ach-3102
- ach-3102
- ach-3102
- odalasvir
- odalasvir
- odalasvir
- odalasvir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03277755 | Phase 1 | Sep 11, 2017 | Johnson and Johnson |
| NCT03155893 | Phase 1 | May 12, 2017 | Johnson and Johnson |
| NCT03059303 | Phase 1 | Feb 20, 2017 | Johnson and Johnson |
| NCT02993250 | Phase 2 | Dec 21, 2016 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02945020 | Phase 1 | Nov 10, 2016 | Johnson and Johnson |
| NCT02765490 | Phase 2 | Nov 9, 2016 | Johnson and Johnson |
| NCT02961660 | Phase 1 | Nov 9, 2016 | Johnson and Johnson |
| NCT02889367 | Phase 1 | Sep 12, 2016 | Johnson and Johnson |
| NCT02885454 | Phase 1 | Aug 1, 2016 | Johnson and Johnson |
| NCT02821858 | Phase 1 | Jun 1, 2016 | Johnson and Johnson |
| NCT02824315 | Phase 1 | May 1, 2016 | Johnson and Johnson |
| NCT02569710 | Phase 2 | Oct 31, 2015 | Alios BioPharma |
| NCT02512562 | Phase 1 | Jul 1, 2015 | Achillion Pharmaceuticals, Alios BioPharma |
| NCT01849562 | Phase 2 | Apr 1, 2013 | Achillion Pharmaceuticals |
| NCT01700179 | Phase 1 | Sep 1, 2012 | Achillion Pharmaceuticals |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 11 | 11 | 2 | 2016 |
| Achillion Pharmaceuticals | For profit | 3 | 2 | 2 | 2012 |
| Alios BioPharma | For profit | 2 | 2 | 2 | 2015 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1